By abhat@reaganud… on
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=Capricor&cntry=&state=&city=&dist=
Sponsor
Capricor Inc.
EA Policies for Disease / Category

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy

CAP-1002 in Severe COVID-19 Disease - Compassionate Use Program

COVID-19 Information

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy - CAP-1002 mitigates the release of anti-inflammatory cytokines as well as macrophage activation in a number of models of inflammation including sepsis and autoimmune diseases. 

CAP-1002 in Severe COVID-19 Disease - Compassionate Use Program

New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 - Over the course of one month, six critically ill COVID-19 patients, all suffering from acute respiratory distress syndrome (ARDS) and five of whom were on mechanical ventilatory support, were safely treated with CAP-1002. Of the six patients treated, four of them have been discharged. 

Stage
Expanded Access
Company Type
Late Onset Intervention